EP1047430A1 - A gel-form pharmaceutical preparation - Google Patents
A gel-form pharmaceutical preparationInfo
- Publication number
- EP1047430A1 EP1047430A1 EP98962440A EP98962440A EP1047430A1 EP 1047430 A1 EP1047430 A1 EP 1047430A1 EP 98962440 A EP98962440 A EP 98962440A EP 98962440 A EP98962440 A EP 98962440A EP 1047430 A1 EP1047430 A1 EP 1047430A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydrocortisone
- gellant
- gel
- formulation according
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- the invention relates to a corticosteroid-containing pharmaceutical preparation intended for topical use.
- Corticosteroids constitute a large group of compounds with a pregnene or pregnadiene backbone and with versatile medical uses. In particular they are used topically as anti-inflammatory dermatological medicines.
- Examples of corticosteroids on the market include hydrocortisone, dexamethasone, betamethasone, methylprednisolone, prednisolone, prednisone, beclomethasone, fludrocortisone, triamsinolone, desonide, fluprednidene, clobetasone, alclomethasone, momethasone, desoxymethasone, fluosinonide, budesonide and fluosinolone .
- ester-form glucocorticoids such as betamethasonide propionate
- Carbomer i.e. carboxyvinyl polymer
- Hydrocortisone gels are not available on the market. Attempts to prepare a hydrocortisone gel by using conventional gellants such as Carbomer polymer have failed owing to the poor stability of hydrocortisone.
- a corticosteroid-containing pharmaceutical formulation according to the invention is characterized in that the formulation has been brought to gel form by means of a gellant, the gellant being hydroxyalkyl cellulose.
- the corticosteroid may be any pharmaceutically acceptable corticosteroid.
- the corticosteroid is hydrocortisone.
- the hydroxyalkyl cellulose used as the gellant is hydroxyethyl cellulose or hydroxypropyl cellulose, in particular hydroxyethyl cellulose.
- the solvent used is preferably a mixture of water and a lower alcohol, such as ethanol or propanol.
- a mixture of water and ethanol or of water and isopropanol is especially preferable .
- Glycerol or propylene glycol is preferably added to the formulation in order to prevent skin drying caused by the alcohol (ethanol).
- alcohol ethanol
- some oil component such as Cetiol SN (cetearyl- isononanoate)
- suitable perfumes and preservatives include methylparahydroxybenzoate, propyl- parahydroxybenzoate and benzyl alcohol.
- hydrocortisone-containing gel batches I, II, III and IV were prepared. Batches I and II were prepared on a laboratory scale (1000 g/batch) and batches III and IV were prepared on an industrial scale (150 kg/batch). The soft gels were packed into polyethylene tubes. The stability of the gels was monitored for 18 months (batch I), 12 months (batch II) and 3 months (batches III and IV).
- the gels were prepared as follows: HEC was added to a mixture of water and ethanol (containing only a portion of the ethanol) while stirring, and the mixture was allowed to gel. Thereafter the glycerol was added while stirring. The balance of the ethanol was added while stirring. Thereafter the active ingredient was added to the gel while stirring.
- the batches were stored at a relative humidity of 60 %.
- the temperature was 25 °C (batches I, III and IV) and respectively 20 °C (batch II).
- the amount of degradation products may be at maximum 5 %, the amount of hydrocortisone should be 9.0 - 11.0 mg/g, and the pH should be 5 - 8.5.
- hydrocortisone gel formulations A, B, C and D were prepared, in which the gellant used was carboxyvinyl polymer Carbomer 980 or Carbomer 940, or polymer Stabileze R QM, which is a copolymer of methylvinyl ether and maleic acid anhydride, cross- bridged with 1 , 9-decadiene .
- These gellants yield a very low pH value (the pH of a 1 % aqueous dispersion of Carbomer polymer is 2.5 - 3.0), and therefore sodium hydroxide was added to adjust the pH to the desired range.
- the auxiliary compositions and hydrocortisone concentrations of the preparations are shown in Table 1, which also shows the stabilities of the preparations .
- Table 1 shows that, already after three months of storage, a large quantity of degradation products of hydrocortisone had formed. After six months of storage the concentration of hydrocortisone degradation products in preparations A, B and D clearly exceeded the guideline values (guideline value at maximum 5 % ) , and the concentration of degradation products in preparation C was also very high (4 %).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical formulation which contains a corticosteroid and a solvent. According to the invention the formulation is brought to gel form by using a gellant which is a hydroxyalkyl cellulose, in particular hydroxyethyl cellulose or hydroxypropyl cellulose.
Description
A GEL-FORM PHARMACEU ICAL PREPARATION
The invention relates to a corticosteroid-containing pharmaceutical preparation intended for topical use.
Corticosteroids constitute a large group of compounds with a pregnene or pregnadiene backbone and with versatile medical uses. In particular they are used topically as anti-inflammatory dermatological medicines. Examples of corticosteroids on the market include hydrocortisone, dexamethasone, betamethasone, methylprednisolone, prednisolone, prednisone, beclomethasone, fludrocortisone, triamsinolone, desonide, fluprednidene, clobetasone, alclomethasone, momethasone, desoxymethasone, fluosinonide, budesonide and fluosinolone .
Common forms of preparations include solutions, ointments, creams and liniments. Certain ester-form glucocorticoids , such as betamethasonide propionate, have also been prepared as a gel in which Carbomer, i.e. carboxyvinyl polymer, has been used as the gellant.
Hydrocortisone gels are not available on the market. Attempts to prepare a hydrocortisone gel by using conventional gellants such as Carbomer polymer have failed owing to the poor stability of hydrocortisone.
We have now observed, surprisingly, that by using hydroxyalkyl cellulose, in particular hydroxyethyl cellulose, as the gellant, very stable corticosteroid gels are obtained.
The characteristics of the invention are given in Claim 1.
A corticosteroid-containing pharmaceutical formulation according to the invention is characterized in that the
formulation has been brought to gel form by means of a gellant, the gellant being hydroxyalkyl cellulose.
The corticosteroid may be any pharmaceutically acceptable corticosteroid. Preferably the corticosteroid is hydrocortisone.
According to a preferred embodiment, the hydroxyalkyl cellulose used as the gellant is hydroxyethyl cellulose or hydroxypropyl cellulose, in particular hydroxyethyl cellulose.
The solvent used is preferably a mixture of water and a lower alcohol, such as ethanol or propanol. A mixture of water and ethanol or of water and isopropanol is especially preferable .
Glycerol or propylene glycol is preferably added to the formulation in order to prevent skin drying caused by the alcohol (ethanol). For this purpose it is also possible to add some oil component, such as Cetiol SN (cetearyl- isononanoate) . It is also possible to add suitable perfumes and preservatives. Examples of suitable preservatives include methylparahydroxybenzoate, propyl- parahydroxybenzoate and benzyl alcohol.
The invention is described in greater detail with the help of the following, non-limiting examples.
Example 1
Hydrocortisone gels in which hydroxyethyl cellulose (HEC) is used as the gellant
Four hydrocortisone-containing gel batches I, II, III and IV were prepared. Batches I and II were prepared on a laboratory scale (1000 g/batch) and batches III and IV were prepared on an industrial scale (150 kg/batch). The soft
gels were packed into polyethylene tubes. The stability of the gels was monitored for 18 months (batch I), 12 months (batch II) and 3 months (batches III and IV). The gels were prepared as follows: HEC was added to a mixture of water and ethanol (containing only a portion of the ethanol) while stirring, and the mixture was allowed to gel. Thereafter the glycerol was added while stirring. The balance of the ethanol was added while stirring. Thereafter the active ingredient was added to the gel while stirring.
Gel compositions (mg/g):
Batches I, Batch II III and IV
Hydrocortisone 10.00 10.00
Hydroxyethyl cellulose 15.00 15.00 Glycerol (99.5 %) 60.00
Ethanol (96 %) 500.00 500.00
Purified water 415.00 475.00
Stability tests:
The batches were stored at a relative humidity of 60 %. The temperature was 25 °C (batches I, III and IV) and respectively 20 °C (batch II).
According to the objective, the amount of degradation products may be at maximum 5 %, the amount of hydrocortisone should be 9.0 - 11.0 mg/g, and the pH should be 5 - 8.5.
Results:
Batch I
Period of storage Degradation Hydrocortisone PH months products % mg/g
Beginning of test 0.6 10.2 7.5
3 months 0.7 10.1 5.8
7 2.3 10.1 5.7
12 " 1.9 10.1 5.7
18 " 1.9 9.5 5.7
Batch II
Period of storage Degradation Hydrocortisone PH months products % mg/g
Beginning of test *) *) *)
12 months 2.2 10.3 5.6
*) not determined
Batch III
Period of storage Degradation Hydrocortisone pH months products % mg/g
Beginning of test 0.6 10.3 6.6
3 months 0.7 9.8 6.8
Batch IV
Period of storage Degradation Hydrocortisone pH months products % mg/g
Beginning of test 0.55 10.2 7 3 months 0.8 10.2 7
The results show that all of the batches remained well within the guideline values as regards hydrocortisone concentration, hydrocortisone degradation products and pH .
Example 2
Hydrocortisone gels in which Carbomer or Stabileze polymer was used as the gellant
For the sake of comparison, four hydrocortisone gel formulations A, B, C and D were prepared, in which the gellant used was carboxyvinyl polymer Carbomer 980 or Carbomer 940, or polymer StabilezeR QM, which is a copolymer of methylvinyl ether and maleic acid anhydride, cross- bridged with 1 , 9-decadiene . These gellants yield a very low pH value (the pH of a 1 % aqueous dispersion of Carbomer polymer is 2.5 - 3.0), and therefore sodium hydroxide was added to adjust the pH to the desired range. The auxiliary compositions and hydrocortisone concentrations of the preparations are shown in Table 1, which also shows the stabilities of the preparations .
Table 1 shows that, already after three months of storage, a large quantity of degradation products of hydrocortisone had formed. After six months of storage the concentration of hydrocortisone degradation products in preparations A, B and D clearly exceeded the guideline values (guideline value at maximum 5 % ) , and the concentration of degradation products in preparation C was also very high (4 %).
The examples given above clearly show that highly stable hydrocortisone gels are obtained by using hydroxyethyl cellulose as the gellant. Although test results have not been presented, it can be assumed that corresponding results would be obtained also with respect to other corticosteroids and when using other hydroxyalkyl celluloses, in particular hydroxypropyl cellulose.
Table 1
The above embodiments of the invention are only examples of the implementation of the idea of the invention. For a person skilled in the art it is clear that the various embodiments of the invention may vary within the claims presented below.
Claims
1. A pharmaceutical formulation comprising a corticosteroid and a solvent, characterized in that the formulation has been brought to gel form by using a gellant, the gellant being a hydroxyalkyl cellulose.
2. A formulation according to Claim 1, characterized in that the corticosteroid is hydrocortisone.
3. A formulation according to Claim 1 or 2, characterized in that the hydroxyalkyl cellulose is hydroxyethyl cellulose or hydroxypropyl cellulose.
4. A formulation according to Claim 1, 2 or 3 , characterized in that the solvent is a mixture of water and a lower alcohol .
5. A formulation according to any of the above claims, characterized in that the corticosteroid is hydrocortisone, the gellant is hydroxyethyl cellulose, and the solvent is a mixture of water and ethanol .
6. A formulation according to Claim 5, characterized in that it additionally contains glycerol.
7. A formulation according to Claim 5 or 6 , characterized in that it additionally contains propylene glycol.
8. A formulation according to Claim 5, characterized in that it contains approx. 0.1 % by weight hydrocortisone and 1 - 2 % by weight hydroxyethyl cellulose.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI974610 | 1997-12-23 | ||
| FI974610A FI974610A0 (en) | 1997-12-23 | 1997-12-23 | Pharmaceutical preparations in gelform |
| PCT/FI1998/001000 WO1999033471A1 (en) | 1997-12-23 | 1998-12-21 | A gel-form pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1047430A1 true EP1047430A1 (en) | 2000-11-02 |
Family
ID=8550206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98962440A Withdrawn EP1047430A1 (en) | 1997-12-23 | 1998-12-21 | A gel-form pharmaceutical preparation |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1047430A1 (en) |
| AU (1) | AU1760799A (en) |
| DK (1) | DK200200342U3 (en) |
| FI (1) | FI974610A0 (en) |
| WO (1) | WO1999033471A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060018852A1 (en) | 2003-08-22 | 2006-01-26 | L'oreal | Compositions containing topical active agents and pentylene glycol |
| US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| EP1888026A4 (en) | 2005-05-27 | 2012-07-04 | Taro Pharmaceuticals North America Inc | A stable liquid formulation comprising desoximetasone and isopropyl myristate with reduced oxidized impurity during long-term storage |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899580A (en) * | 1972-06-30 | 1975-08-12 | Merck & Co Inc | Anti-inflammatory topical gel |
| US4267173A (en) * | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
| EP0112852B1 (en) * | 1982-06-24 | 1988-06-08 | SMITH, Robert Alan | Pharmaceutical gel composition |
| US4775529A (en) * | 1987-05-21 | 1988-10-04 | Schering Corporation | Steroid lotion |
| US5110809A (en) * | 1988-03-21 | 1992-05-05 | Bristol-Myers Squibb Company | Antifungal gel formulations |
| US4866050A (en) * | 1988-04-27 | 1989-09-12 | Ben Amoz Daniel | Ultrasonic transdermal application of steroid compositions |
-
1997
- 1997-12-23 FI FI974610A patent/FI974610A0/en not_active Application Discontinuation
-
1998
- 1998-12-21 WO PCT/FI1998/001000 patent/WO1999033471A1/en not_active Application Discontinuation
- 1998-12-21 EP EP98962440A patent/EP1047430A1/en not_active Withdrawn
- 1998-12-21 AU AU17607/99A patent/AU1760799A/en not_active Abandoned
-
2002
- 2002-11-01 DK DK200200342U patent/DK200200342U3/en not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9933471A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999033471A1 (en) | 1999-07-08 |
| FI974610A0 (en) | 1997-12-23 |
| AU1760799A (en) | 1999-07-19 |
| DK200200342U3 (en) | 2003-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4185100A (en) | Topical anti-inflammatory drug therapy | |
| US4083974A (en) | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether | |
| US5914122A (en) | Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams | |
| US7611727B2 (en) | Pharmaceutical composition for transdermal or transmucous administration | |
| JP5111117B2 (en) | External preparations with improved steroid stability over time | |
| EP0362270B1 (en) | Steroid lotion | |
| US4282216A (en) | Topical anti-inflammatory drug therapy | |
| EP0471872A1 (en) | Antifungal gel formulations | |
| WO2003055445A2 (en) | Compositions and methods for enhancing corticosteriod delivery | |
| JPH09504510A (en) | Antifungal liquid for nails | |
| US4579844A (en) | Topical anti-inflammatory drug therapy | |
| HU200912B (en) | Process for producing composition comprising double solvent system, useful in local application of pharmaceutical active ingredient suitable for treating fungus infections | |
| WO2010084457A1 (en) | A novel dermaceutical cream made using sodium fusidate and steroids | |
| WO2006111426A1 (en) | Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology | |
| JPH0463852B2 (en) | ||
| US4360518A (en) | Topical anti-inflammatory drug therapy | |
| US4473565A (en) | Topical anti-inflammatory drug therapy | |
| EP1047430A1 (en) | A gel-form pharmaceutical preparation | |
| GB1478009A (en) | Pharmaceutical compositions | |
| US5879711A (en) | Stable antiandrogenic gel composition | |
| KR100358081B1 (en) | Steroid anti-inflammatory agent for treatment of stomatitis | |
| NZ235054A (en) | Gel formulation comprising imidazole antifungal agent and a 17-ester steroid anti-inflammatory agent with a co-solvent system and a gelling agent | |
| US8895538B2 (en) | Combination and composition that contains an antimicrobial, a glucocorticoid and an antimycotic | |
| JPS59116212A (en) | Indomethacin-containing cream for external application and its preparation | |
| JPS62215528A (en) | Pharmaceutical for percutaneous administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20000522 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20010806 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20021107 |